Apremilast in the Treatment of Uveitis

An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

Inclusion Criteria:

• patients with vision-threatening autoimmune uveitis
• failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

Exclusion Criteria:

• serious concomitant illness that could interfere with the subject's participation
• previous or current use of an alkylating agent
• use of CYP3A4 inhibitors during the trial
• TNF blocker use within the 8 weeks prior to enrollment